Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 5;14:5415. doi: 10.1038/s41467-023-41218-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — A ELISA for IFN-β content in the supernatant after cisplatin combined indicated treatment. B mRNA expression of Trp catabolic enzymes after treated with cisplatin. C HPLC-MS detection of Kyn levels after treated with cisplatin or RT under indicated medium. D Immunoassay for STING expression after treated with Kyn under indicated medium. E Immunoassay for representative cGAS-STING related genes expression after treated with Kyn under indicated medium. F Immunoassay for representative cGAS-STING related genes expression after treated with cGAMP or Kyn. G HPLC-MS detection of Kyn levels for knocked-out IDO1 cells after indicated treatment. H Immunoassay for IDO1, pSTING, and STING expression of IDO1 knocked-out cells after indicated treatment. I Immunoassay for IDO1 expression (left) and HPLC-MS detection of Kyn levels (right) in MB49-bearing mice after treated with cisplatin or RT (n = 6). J, K Effect of cisplatin (J), and RT (K) combined with 1-MT on MB49 growth (n = 6) (Mean ± SEM). P value by One-way ANOVA (A, I–K). P value by two-tailed t test (C, G). All p value < 0.05 as statistic difference. Error bars represent Mean ± SD, unless otherwise indicated. Three biologically independent experiments were performed (A–H). Source data are provided as a Source Data file.